Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FibroGen

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Earnings Outlook For FibroGen

Earnings Outlook For FibroGen

FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.83.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FibroGen's Earnings: A Preview

FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.66.

Organisations

European Medicines Agency

Medicines and Healthcare products Regulatory Agency

SmileDirectClub

GoodRx Holdings

Myovant Sciences

BioCryst Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

127,179 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play